Scarica l'app Stockscreener
271.77
1.13%
3.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
ALNY Stock Price TodayAlnylam Pharmaceuticals Inc News, Charts, Retail Sentiment - Stocktwits
Alnylam stock trades steady as RNAi pipeline advances and cash position supports development - Ad-hoc-news.de
Alnylam Pharmaceuticals, Inc. (ALNY) stock price, news, quote and history - Yahoo Finance UK
Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
ALNY Maintains Overweight by JP Morgan -- Price Target Lowered t - GuruFocus
Alnylam Pharmaceuticals Price Target Cut to $400.00/Share From $420.00 by JP Morgan - Moomoo
ALNY|Alnylam Pharmaceuticals Inc|Price:269.400|Chg%:+0.660 - TradingKey
US2043QAC1 Bond Profile — Key Metrics - TradingView
Biomarker Collaboration and Licensing Deals Report 2016-2026Featuring Quanterix, Caris Life Sciences, Alnylam Pharmaceuticals, Guardant Health, Eurofins Scientific and More - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Q2 2024 earnings summary - Quartr
Alnylam Stock And 2 US Health Care Names With Earnings In Focus - simplywall.st
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Look At Its 62.57% Potential Upside - DirectorsTalk Interviews
Can Alnylam (ALNY) Turn Early Alzheimer’s RNAi Signals Into a Durable Neuroscience Investment Story? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Could Be 39% Below Fair Value As Alzheimer’s Pipeline Progresses - simplywall.st
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD By Investing.com - Investing.com South Africa
Alnylam slips as recent analyst target cuts appear to overshadow pipeline updates ahead of earnings - Quiver Quantitative
Alnylam Pharmaceuticals stock hits 52-week low at 273.03 USD - Investing.com
Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200 - GlobeNewswire Inc.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (ATAI), Alnylam Pharma (ALNY) and Elevance Health (ELV) - The Globe and Mail
Alnylam Pharmaceuticals (ALNY) Proxy filing Summary - Quartr
Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Priced Below Biotech Peers with Strong Growth - ChartMill
Liquidity Mapping Around (ALNY) Price Events - Stock Traders Daily
Alnylam schedules conference call on second-quarter 2026 results - Bitget
Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results - BioSpace
Alnylam Pharmaceuticals Stock In Shambles: Down 14% With 5-Day Losing Streak - Trefis
Press Release: Alnylam to Webcast Conference Call Discussing Second Quarter 2026 Financial Results - Moomoo
Alnylam Pharmaceuticals Stock: 5 Straight Red Days, Down 14% - Trefis
Alnylam Pharmaceuticals: Commercial Momentum Outweighs TTR Read-Through Concerns (NASDAQ:ALNY) - Seeking Alpha
Alnylam to Host Tenth “RNAi Roundtable” Webcast Series - The National Law Review
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease - BioSpace
ALNY Maintained by B of A Securities -- Price Target Lowered to $410 - GuruFocus
Morgan Stanley Raises its Price Target on Alnylam (ALNY) - Yahoo Finance
BofA Securities Cuts Alnylam Pharmaceuticals Price Target to $410 From $460, Maintains Buy Rating - Moomoo
Alnylam Pharmaceuticals' Q2 Results to Determine 2026 Revenue Outlook, BofA Securities Says - Moomoo
Stifel reiterates Buy rating on Alnylam stock amid trial debate By Investing.com - Investing.com Canada
BofA cuts Alnylam stock price target on conservative outlook By Investing.com - Investing.com Canada
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shows Accelerating Momentum as a High Growth Stock - ChartMill
Alnylam Pharmaceuticals Price Target Raised to $485.00/Share From $470.00 by HC Wainwright & Co. - Moomoo
ALNY Maintains Rating by Truist Securities -- Price Target Lowered to $410 - GuruFocus
ALNY Maintained by HC Wainwright & Co. -- Price Target Raised to $485 - GuruFocus
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions - MarketBeat
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $485 - Moomoo
Truist cuts Alnylam stock price target to $410 on ATTR outlook - Investing.com Canada
Alnylam Pharmaceuticals (ALNY) Stock Analysis: A Strong Buy Opportunity with 47% Upside Potential - DirectorsTalk Interviews
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) After Rival ATTR-CM Setback And New Partnerships - Sahm
Alnylam Pharmaceuticals (ALNY) Could Be 28% Undervalued Following Rival ATTR Trial Failure - Sahm
Truist Financial Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating - Moomoo
Pfizer, Alnylam, BridgeBio gain after late-stage trial setback for Astra/Ionis - MSN
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations? - Yahoo Finance
AstraZeneca's $27 Billion TTR Wipeout Hands Alnylam the Market — But Its Own Trial Has the Same Flaw - finance.biggo.com
Ionis Pharmaceuticals Drops Another 9% as Bad News Piles Up - 24/7 Wall St.
Is Rival ATTR-CM Trial Failure and New AI Deals Altering The Investment Case For Alnylam (ALNY)? - Yahoo Finance
3 Healthcare Stocks Investors Are Turning To As Growth Valuations Look Stretched - Sahm
0.27%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):